.
BTW, Grifols to acquire 100% Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome.
From Grifols webpage:
"Bioscience
With the largest network of plasma donation centers in the world, the Bioscience Division is a leading producer of plasma-derived medicines for the treatment of rare, chronic and sometimes life-threatening conditions.
To help ensure a reliable, consistent source of plasma medicines worldwide, we have an all-inclusive process that begins with plasma collection and continues through fractionation, purification and production.
Plasma proteins
- Immunoglobulins, particularly intravenous immunoglobin (IVIG) in immunology. Used mainly to treat primary immunodeficiencies and chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological condition.
- Albumin to restore circulating blood volume and protein loss in such physiopathological conditions as liver cirrhosis, trauma, cardio-circulatory insufficiency or severe burns. Research currently underway to assess its potential to treat Alzheimer's.
- Alpha-1-antitrypsin to treat alpha-1-antitrypsin deficiency, a rare genetic disease that can lead to severe lung diseases such as emphysema.
- Factor VIII and other clotting factors for hematology used primarily to treat hemophilia and other conditions that may result in bleeding episodes, including internal bleeding with subsequent tissue and organ damage.
- Other specialty hyperimmune immunoglobulins to treat potentially fatal infections such as rabies, tetanus, hepatitis B and Rh incompatibility.
Plasma quality and product safety
Plasma is the clear, liquid portion of the blood. About 90% is composed of water, while the remaining 10% contains hundreds of essential proteins. Without enough of one of these proteins, a person could have a life-threatening condition.
Donor health and patient safety are our top priorities. We ensure that all plasma donor centers are held to the highest quality and safety standards established by US and European health authorities.
Plasma collection is performed in highly controlled environments by professionally licensed and trained staff. This allows us to maintain very high standards of quality and safety for the medications we produce."
In other words, Grifols, with Alkahest adquisition, reinforces its leadership on plasma-derived compounds market, probably and, if so precisely, including the production of the sort of blood components Elixir success is based on.
Looks like an interesting 'emerging market' (rejuvenating one?) move that might backup, somehow so far, Karcher's and team findings, IMHO. I would keep a close eye on this, because I suspect there is more to come sooner than later. Grifols is well known for very smart strategic actions up to now.
.
Edited by Engadin, 07 September 2020 - 11:16 PM.